Adverse reproductive health outcomes in a cohort of young women with breast cancer exposed to systemic treatments (original) (raw)
Serum AMH level as a marker of acute and long-term effects of chemotherapy on the ovarian follicular content: a systematic review
maeliss peigne
Reproductive Biology and Endocrinology, 2014
View PDFchevron_right
Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer
Mikkel Rosendahl, Tom Kelsey
View PDFchevron_right
Impact of breast cancer treatment on fertility
Olivia Pagani
tara.tcd.ie
View PDFchevron_right
AMH as an ovarian function predictor in premenopausal female breast cancer patients receiving chemotherapy is effective only for those over 35 years old
sixuan Liu
2020
View PDFchevron_right
Anti-Mullerian Hormone and Antral Follicle Count Reveal a Late Impairment of Ovarian Reserve in Patients Undergoing Low-Gonadotoxic Regimens for Hematological Malignancies
Alessio Perandini
The Oncologist, 2013
View PDFchevron_right
Patients with cancer at the margins of reproductive age had reduced levels of anti-Müllerian hormone compared with patients experiencing infertility
Edgar Mocanu
International Journal of Gynecology & Obstetrics, 2016
View PDFchevron_right
Toward a better follow-up of ovarian recovery in young women after chemotherapy with a hypersensitive antimüllerian hormone assay
Didier Dewailly
Fertility and Sterility, 2014
View PDFchevron_right
Acute onset of ovarian dysfunction in young females after start of cancer treatment
Ingrid Øra
Pediatric Blood & Cancer, 2013
View PDFchevron_right
Anti-Müllerian Hormone and Antral Follicle Count Reveal a Late Impair- Ment of Ovarian Reserve in Patients Undergone Low Gonadotoxic Regimens for Haematological Malignancies
Alessio Perandini
2013
View PDFchevron_right
Comparing the Gonadotoxicity of Multiple Breast Cancer Regimens: Important Understanding for Managing Breast Cancer in Pre-Menopausal Women
Piero Fregatti
Breast Cancer: Targets and Therapy, 2021
View PDFchevron_right
Amenorrhea, fertility preservation, and counseling among young women treated with anthracyclines and taxanes for early-stage breast cancer, a retrospective study
omar shahin
Medicine, 2020
View PDFchevron_right
The PREgnancy and FERtility (PREFER) Study Investigating the Need for Ovarian Function and/or Fertility Preservation Strategies in Premenopausal Women With Early Breast Cancer
Piero Fregatti
Frontiers in Oncology, 2021
View PDFchevron_right
Pretreatment antimüllerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy
Yasmin Gosiengfiao, Maureen Prewitt
Fertility and Sterility, 2013
View PDFchevron_right
Antral Follicles Count and Anti-Müllerian Hormone Levels after Gonadotoxic Chemotherapy in Patients with Breast Cancer: Cohort Study
Helena Corleta
Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia, 2017
View PDFchevron_right
Adjuvant therapy with GnRH agonists/tamoxifen in breast cancer could be a good council for patients with hormone receptor-positive tumors and wish to preserve fertility
Jose Franco Junior
JBRA Assisted Reproduction
View PDFchevron_right
Avaliação da reserva ovariana em mulheres com câncer de mama submetidas à quimioterapia
Ângela Davila
2013
View PDFchevron_right
Cancer and fertility preservation: fertility preservation in breast cancer patients
Heinz Koelbl
Breast Cancer Research, 2008
View PDFchevron_right
Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age
Anders Juul
Fertility and Sterility, 2010
View PDFchevron_right
Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: A GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology
Ivan Moschetti
European journal of cancer (Oxford, England : 1990), 2017
View PDFchevron_right
Assessing The Impact Of Cancer Therapies On Ovarian Reserve
jill ginsberg
Fertility and Sterility
View PDFchevron_right
Fertility preservation in women with breast cancer undergoing adjuvant chemotherapy: a systematic review
Marcelo Cruz
Fertility and Sterility, 2010
View PDFchevron_right
Chemotherapy-Related Amenorrhea in Breast Cancer: Review of the Main Published Studies, Biomarkers of Ovarian Function and Mechanisms Involved in …
Martine Berliere
intechopen.com
View PDFchevron_right
Impact of cancer therapies on ovarian reserve
Maureen Prewitt
Fertility and Sterility, 2012
View PDFchevron_right
Comment on: sexual and fertility adverse effects associated with chemotherapy treatment in women
Zeev Blumenfeld
Expert Opinion on Drug Safety, 2014
View PDFchevron_right
REPRODUCTIVE SEQUELAE OF CANCER TREATMENT
Mark Shahin
Obstetrics and Gynecology Clinics of North America, 1998
View PDFchevron_right
Antimüllerian hormone and antral follicle count are lower in female cancer survivors and healthy women taking hormonal contraception
Mary Sammel
Fertility and sterility, 2014
View PDFchevron_right
Preservation of Fertility and Ovarian Function and Minimizing Chemotherapy-Induced Gonadotoxicity in Young Women
Zeev Blumenfeld
Journal of The Society for Gynecologic Investigation, 1999
View PDFchevron_right
Long-Term Outcomes With Pharmacological Ovarian Suppression During Chemotherapy in Premenopausal Early Breast Cancer Patients
Piero Fregatti
Journal of the National Cancer Institute, 2021
View PDFchevron_right
Fertility and adjuvant treatment in young women with breast cancer
Kathryn Ruddy
The Breast, 2007
View PDFchevron_right
Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer
Francesco Torino, Francesco Schittulli
2014
View PDFchevron_right
Risk of gonadotoxicity with immunotherapy and targeted agents remains an unsolved but crucial issue
Stefano Spinaci
European Journal of Clinical Investigation
View PDFchevron_right
Ovarian Function and Fertility Preservation in Breast Cancer: Should Gonadotropin-Releasing Hormone Agonist be administered to All Premenopausal Patients Receiving Chemotherapy?
Cynthia Villarreal-Garza
Clinical Medicine Insights: Reproductive Health
View PDFchevron_right